VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo

OBJECTIVE: We aimed to develop a novel anti-HIF-1α intrabody to decrease gemcitabine resistance in pancreatic cancer patients. METHODS: Surface plasmon resonance and glutathione S-transferase pull-down assays were conducted to identify the binding affinity and specificity of anti-HIF-1α VHH212 [a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Guangbo, Hu, Min, Ren, He, Wang, Jiewen, Cheng, Xin, Li, Ruowei, Yuan, Bo, Balan, Yasmine, Bai, Zixuan, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330535/
https://www.ncbi.nlm.nih.gov/pubmed/33830713
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330535/
https://www.ncbi.nlm.nih.gov/pubmed/33830713
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0568

Ejemplares similares